PRKAA1

Pathway Diagram

flowchart TD
    PRKAA1["PRKAA1"]
    style PRKAA1 fill:#006494,stroke:#4fc3f7,stroke-width:3px,color:#e0e0e0
    TREM2["TREM2"]
    PRKAA1 -->|"upregulates"| TREM2
    Reactive_Oxygen_Species["Reactive Oxygen Species"]
    PRKAA1 -->|"regulates"| Reactive_Oxygen_Species
    Parkinson_s_Disease["Parkinson's Disease"]
    PRKAA1 -->|"regulates"| Parkinson_s_Disease
    ULK1["ULK1"]
    PRKAA1 -->|"activates"| ULK1
    AUTOPHAGY["AUTOPHAGY"]
    PRKAA1 -->|"activates"| AUTOPHAGY
    demyelination["demyelination"]
    PRKAA1 -->|"associated with"| demyelination
    Als["Als"]
    PRKAA1 -->|"therapeutic target"| Als
    Cancer["Cancer"]
    PRKAA1 -->|"therapeutic target"| Cancer
    h_b0cda336["h-b0cda336"]
    h_b0cda336 -->|"therapeutic target"| PRKAA1
    h_43f72e21["h-43f72e21"]
    h_43f72e21 -->|"therapeutic target"| PRKAA1
    h_b0cda336 -->|"targets gene"| PRKAA1
    h_43f72e21 -->|"targets gene"| PRKAA1
    EGCG["EGCG"]
    EGCG -->|"targets"| PRKAA1
    MIR130B["MIR130B"]
    MIR130B -->|"downregulates"| PRKAA1
    h_b0cda336 -->|"targets"| PRKAA1
    h_43f72e21 -->|"targets"| PRKAA1
    style TREM2 fill:#1b5e20,stroke:#4fc3f7,color:#e0e0e0
    style Reactive_Oxygen_Species fill:#888,stroke:#4fc3f7,color:#e0e0e0
    style Parkinson_s_Disease fill:#ef5350,stroke:#4fc3f7,color:#e0e0e0
    style ULK1 fill:#1b5e20,stroke:#4fc3f7,color:#e0e0e0
    style AUTOPHAGY fill:#5d4400,stroke:#4fc3f7,color:#e0e0e0
    style demyelination fill:#6d3000,stroke:#4fc3f7,color:#e0e0e0
    style Als fill:#ef5350,stroke:#4fc3f7,color:#e0e0e0
    style Cancer fill:#ef5350,stroke:#4fc3f7,color:#e0e0e0
    style h_b0cda336 fill:#888,stroke:#4fc3f7,color:#e0e0e0
    style h_43f72e21 fill:#888,stroke:#4fc3f7,color:#e0e0e0
    style EGCG fill:#006494,stroke:#4fc3f7,color:#e0e0e0
    style MIR130B fill:#1b5e20,stroke:#4fc3f7,color:#e0e0e0

Overview

PRKAA1 (Protein Kinase AMP-Activated Catalytic Subunit Alpha 1) encodes the α1 catalytic subunit of AMP-activated protein kinase (AMPK), the master cellular energy sensor and metabolic regulator. AMPK is a heterotrimeric complex composed of a catalytic α subunit (PRKAA1/α1 or PRKAA2/α2), a scaffolding β subunit (PRKAB1/β1 or PRKAB2/β2), and a regulatory γ subunit (PRKAG1/γ1, PRKAG2/γ2, or PRKAG3/γ3). While the α2 subunit (PRKAA2) predominates in neurons, the α1 subunit is the major isoform in astrocytes, microglia, oligodendrocytes, and brain endothelial cells, making PRKAA1 a critical regulator of glial metabolism, neuroinflammation, blood-brain barrier function, and myelination in the context of neurodegenerative disease.

Gene Structure and Expression

PRKAA1 spans approximately 65 kb on chromosome 5p13.1 and contains 10 exons encoding a 559 amino acid protein. The promoter region contains binding sites for CREB, SP1, and FOXO transcription factors. Unlike the highly regulated α2 subunit, PRKAA1/α1 is constitutively expressed across most tissues, reflecting its role as a ubiquitous metabolic sensor.

In the brain, PRKAA1/α1 shows a cell-type-specific expression pattern that is complementary to PRKAA2/α2. While α2 predominates in neurons, α1 is the dominant catalytic isoform in:

• Astrocytes: AMPKα1 regulates astrocyte glycogen metabolism, lactate shuttle to neurons, and reactive astrogliosis

• Microglia: AMPKα1 controls microglial metabolic reprogramming, phagocytosis, and inflammatory cytokine production

• Oligodendrocytes: AMPKα1 regulates lipid biosynthesis for myelination and oligodendrocyte maturation

• Brain endothelial cells: AMPKα1 maintains tight junction integrity and BBB function

The Allen Brain Atlas shows moderate, widespread PRKAA1 expression with enrichment in white matter tracts and periventricular regions, consistent with its glial predominance.

Protein Function and Mechanism

AMPKα1 contains the following functional domains:

• Kinase domain (aa 27-279): Serine/threonine kinase domain with activation loop (T172) — the critical phosphorylation site for AMPK activation

• Autoinhibitory domain (AID) (aa 313-335): Intramolecular domain that suppresses kinase activity in the absence of AMP/ADP binding to the γ subunit

• α-linker (aa 336-395): Flexible linker connecting AID to the C-terminal regulatory domain; undergoes conformational change upon AMP binding to the γ subunit, relieving autoinhibition

• C-terminal domain (CTD/α-CTD) (aa 396-559): Mediates interaction with the β subunit and stabilizes the heterotrimeric complex

AMPK activation is triggered by metabolic stress signals that increase the cellular AMP:ATP or ADP:ATP ratio:

1. AMP/ADP binding: γ subunit binds AMP or ADP, inducing a conformational change transmitted through the β subunit to the α-linker, releasing the AID from the kinase domain

2. LKB1 phosphorylation: The upstream kinase LKB1 (STK11) phosphorylates T172 in the activation loop — this is the primary activation mechanism in most cells

3. CaMKKβ phosphorylation: In neurons and cells experiencing calcium influx, CaMKKβ provides an alternative T172 phosphorylation mechanism independent of AMP changes

4. Allosteric activation: AMP binding directly activates the kinase 2-5 fold and protects T172 from dephosphorylation by PP2C phosphatases

Key AMPKα1 substrates and functions in the CNS:

• ACC1/ACC2: Phosphorylation inhibits fatty acid synthesis and activates fatty acid oxidation — critical for oligodendrocyte lipid metabolism and microglial metabolic reprogramming

• ULK1 (S317, S555): Phosphorylation activates autophagy initiation — AMPKα1 in astrocytes promotes autophagic clearance of protein aggregates

• TFEB (S211): Phosphorylation promotes lysosomal biogenesis — glial aggregate clearance pathway

• mTORC1 (via TSC2/Raptor): AMPKα1 inhibits mTOR signaling to reduce anabolic metabolism during energy stress

• NF-κB (p65 S536): AMPKα1 suppresses NF-κB inflammatory signaling in microglia and astrocytes

• HMGCR: Phosphorylation inhibits cholesterol synthesis — relevant to brain cholesterol homeostasis and ApoE metabolism

Disease Associations

Alzheimer’s Disease

In AD, AMPKα1 function is impaired in astrocytes and microglia, contributing to disease progression through multiple mechanisms:

• Astrocyte metabolic failure: Reduced AMPKα1 activity impairs astrocyte glucose uptake and lactate production, starving neurons of metabolic support. AD astrocytes show diminished AMPK-dependent glycogen mobilization.

• Microglial dysfunction: AMPKα1 inactivation in microglia promotes the shift from oxidative phosphorylation to aerobic glycolysis (Warburg-like effect), driving pro-inflammatory M1 polarization and impairing Aβ phagocytosis. Restoring AMPKα1 activity with metformin or AICAR promotes anti-inflammatory M2 polarization and enhances amyloid clearance.

• BBB breakdown: AMPKα1 inactivation in brain endothelial cells disrupts tight junction protein expression (claudin-5, occludin, ZO-1), contributing to BBB permeability observed in AD.

• Cholesterol dysregulation: AMPKα1-HMGCR axis disruption alters brain cholesterol homeostasis, affecting ApoE lipidation and Aβ clearance.

Parkinson’s Disease

In PD, AMPKα1 plays dual roles:

• Microglial inflammation: α-Synuclein fibrils activate TLR2 on microglia, suppressing AMPKα1 and unleashing NF-κB-driven neuroinflammation. AMPKα1 activation with AICAR reduces pro-inflammatory cytokine production and nigral dopaminergic neuron loss in MPTP models.

• Astrocyte neuroprotection: AMPKα1 in astrocytes promotes secretion of neurotrophic factors (GDNF, BDNF) and maintains the glutamate-glutamine cycle. AMPKα1 loss in astrocytes exacerbates excitotoxicity in PD.

• Oligodendrocyte dysfunction: AMPKα1 impairment reduces myelin lipid synthesis, contributing to white matter degeneration observed in PD.

ALS

In ALS, AMPKα1 dysregulation in glial cells accelerates motor neuron degeneration:

• Astrocyte toxicity: SOD1-mutant astrocytes show reduced AMPKα1 activity, impaired autophagy of mutant SOD1 aggregates, and increased release of neurotoxic factors

• Microglial activation: AMPKα1 loss in microglia potentiates TDP-43-triggered neuroinflammation

• Oligodendrocyte degeneration: Early oligodendrocyte loss in ALS correlates with AMPKα1 inactivation and impaired myelination

Huntington’s Disease

In HD, AMPKα1 is aberrantly activated in striatal astrocytes by mutant huntingtin-induced metabolic stress. While initially compensatory, chronic AMPKα1 activation drives excessive autophagy and astrocyte dysfunction, paradoxically worsening neuronal support. The α1/α2 balance is disrupted in HD striatum, with relative α1 upregulation and α2 downregulation.

Common Variants

Therapeutic Implications

AMPK activators are among the most studied neuroprotective compounds:

• Metformin: Indirect AMPK activator (via LKB1); epidemiological studies show reduced dementia risk in diabetic patients on metformin; clinical trials in AD and PD ongoing

• AICAR (acadesine): Cell-permeable AMP analog; activates AMPKα1/α2; anti-inflammatory in microglia but limited BBB penetration

• A-769662 and compound 991: Direct AMPKα1β1-selective activators; bind the ADaM (allosteric drug and metabolite) site at the α-β interface; improved isoform selectivity for glial-targeted activation

• Salicylate (aspirin metabolite): Direct AMPKα1β1 activator; epidemiological associations with reduced AD risk may partly reflect glial AMPK activation

• Trehalose: mTOR-independent autophagy inducer that also activates AMPK; promotes aggregate clearance in multiple neurodegenerative models

• Resveratrol: Indirect AMPK activator via SIRT1-LKB1 axis; neuroprotective in preclinical models but poor bioavailability limits clinical translation

See Also

• PRKAA2 — AMPKα2 catalytic subunit, neuronal isoform

• MTOR — mTOR kinase, reciprocally regulated by AMPK

• STK11 — LKB1, upstream AMPK kinase

• LATS1 — Hippo pathway kinase, AMPK-Hippo crosstalk

• LATS2 — Hippo pathway kinase, AMPK-Hippo crosstalk

• SIRT1 — AMPK-SIRT1 metabolic axis

External Links

• NCBI Gene: PRKAA1

• UniProt: Q13131

• OMIM: 602739

• GeneCards: PRKAA1

• Allen Brain Atlas: PRKAA1

• PhosphoSitePlus: PRKAA1